OrganoScreen Platform
Ex vivo cancer modeling and functional screening
Heads:
Dr. Julie Rivière; Dr. Pierre Savagner
Objectives
A preclinical drug discovery and testing platform based on patient-derived models, designed to generate an institutional biobank and explore drug and immune resistance mechanisms using cellular and molecular tools to support new target discovery and personalized medicine.
Operator (s)
Technology and expertises
Cancer organoid engineering from patient biopsies, using tailored cell compositions, relevant matrices, optimized culture media and microfluidic designs.
Screening methods based on CRISPR/Cas9 tools.
Short- and long-term monitoring using functional metabolic markers, image analysis and holotomography for characterization, quantification and IC50 determination.
Services and activities
Organoid engineering, characterization and biobanking.
Cohort development across multiple cancer types (catalogue).
Automated compound testing and screening.
CRISPR/Cas9-based loss-of-function screening to assess resistance and sensitivity.